Early cancer detection based on analysis of single extracellular vesicles

Mercy BioAnalytics is pioneering advancements in early cancer detection through its innovative Mercy Halo™ platform. This technology leverages low-cost quantitative Polymerase Chain Reaction (qPCR) methods and focuses on extracellular vesicles (EVs), which are stable and abundant particles released by all cells, including tumor cells. By identifying specific combinations of cancer-associated biomarkers present on individual EVs, the Mercy Halo™ platform aims to create highly sensitive and specific blood-based tests. These tests are designed to detect cancer at its earliest stages, significantly improving the chances of successful treatment and patient outcomes.

The company emphasizes the importance of rigorous scientific validation in developing its tests. Mercy BioAnalytics conducts clinical studies to ensure that their tests can effectively identify pre-clinical disease in individuals who show no signs or symptoms of cancer. This commitment to evidence-driven solutions is central to their mission of enhancing early detection capabilities, which they believe is crucial in the fight against cancer. By focusing on the unique properties of exosomes, which carry cancer-specific markers in greater abundance than circulating DNA, Mercy BioAnalytics aims to overcome the limitations of traditional testing methods and provide accessible, low-cost options for early cancer diagnosis.

United States

Mercy BioAnalytics is on a mission to save lives and relieve suffering across the globe through the early detection of cancer. We have developed a novel liquid biopsy assay platform which interrogates tumor-derived extracellular vesicles, which are abundant in blood and carry information about their cell of origin, enabling detection of cancer even in at the earliest stages. 

Mercy BioAnalytics

Company Details